Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors

p38 mitogen-activated protein kinase (p38 MAPK) is an important signal transducing enzyme involved in many cellular regulations, including signaling pathways, pain and inflammation. Several p38 MAPK inhibitors have been developed as drug candidates to treatment of autoimmune disorders, such as rheum...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2012-08, Vol.54, p.264-271
Main Authors: de Oliveira Lopes, Raquel, Romeiro, Nelilma Correia, de Lima, Cleverton Kleiton F., Louback da Silva, Leandro, Palhares de Miranda, Ana Luisa, Nascimento, Paulo Gustavo B.D., Cunha, Fernando Q., Barreiro, Eliezer J., Lima, Lídia Moreira
Format: Article
Language:English
Subjects:
Analgesic
Animals
Anti-inflammatory
Arthritis
Biological and medical sciences
Carrageenan - pharmacology
Docking
Dose-Response Relationship, Drug
Drug Design
Edema - chemically induced
Edema - drug therapy
Female
Male
Medical sciences
Mice
Miscellaneous
Molecular Docking Simulation
Nociception - drug effects
p38 MAPK
p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors
p38 Mitogen-Activated Protein Kinases - chemistry
p38 Mitogen-Activated Protein Kinases - metabolism
Pharmacology. Drug treatments
Protein Conformation
Protein Kinase Inhibitors - analogs & derivatives
Protein Kinase Inhibitors - chemical synthesis
Protein Kinase Inhibitors - metabolism
Protein Kinase Inhibitors - pharmacology
Rats
Rats, Wistar
Tumor Necrosis Factor-alpha - biosynthesis
Urea - analogs & derivatives
Urea - chemical synthesis
Urea - metabolism
Urea - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:p38 mitogen-activated protein kinase (p38 MAPK) is an important signal transducing enzyme involved in many cellular regulations, including signaling pathways, pain and inflammation. Several p38 MAPK inhibitors have been developed as drug candidates to treatment of autoimmune disorders, such as rheumatoid arthritis. In this paper we reported the docking, synthesis and pharmacological activity of novel urea-derivatives (4a–e) designed as p38 MAPK inhibitors. These derivatives presented good theoretical affinity to the target p38 MAPK, standing out compound 4e (LASSBio-998), which showed a better score value compared to the prototype GK-00687. This compound was able to reduce in vitro TNF-α production and was orally active in a hypernociceptive murine model sensible to p38 MAPK inhibitors. Otherwise, compound 4e presented a dose-dependent analgesic effect in a model of antigen (mBSA)-induced arthritis and anti-inflammatory profile in carrageenan induced paw edema, indicating its potential as a new antiarthritis prototype. The docking, synthesis and pharmacological activity of novel urea-derivatives (4a–e) designed as p38 MAPK inhibitors are reported. Compound 4e (LASSBio-998) was demonstrated to be a new antiarthritis prototype. [Display omitted] ► The ability of urea-derivatives (4a–e) to be recognized by p38 MAPK was determined by docking studies. ► Compound 4e showed a better score value compared to the prototype GK-00687. ► Anti-inflammatory and analgesic activities of compound 4e were demonstrated. ► Compound 4e is a weak inhibitor of TNF-alfa production and p38 MAPK.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2012.05.006